News | May 30, 2022
Glenmark Pharma reports revenue growth of 5.6% YoY in Q4
Glenmark Pharmaceuticals announced its financial results for the fourth quarter ended March 31, 2022
Glenmark Pharmaceuticals announced its financial results for the fourth quarter ended March 31, 2022
The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD), Motrin Oral Suspension, 100 mg/5 mL, of McNeil Consumer Healthcare (McNeil)
OS-SiA is the industry’s first AI-enabled digital scanner that will provide real-time predictive analysis and actionable insights
The Innovation Explorer database of GlobalData’s Disruptor Intelligence Center highlights how blockchain ensures the authenticity of products thereby, improves trust, traceability, and transparency across key sectors
68% of patients receiving Kymriah in the ELARA trial experienced a complete response, with an 86% overall response rate, along with a remarkable safety profile
The campaign aims to promote an integrated view by combining Ayurveda and Yoga to create harmony not just within the body, but also in our minds
Already an existing partner and supplier of ingredients to Medisca, striking this agreement with SUANFARMA involved reinforcing a well-established symbiotic relationship between two companies committed to world-class quality, service, and price
The inspection was a Pre-Approval cum cGMP inspection and it covered 15 ANDAs
The company’s annual sales grew from Rs 548.12 crore in FY 2020-21 to Rs 598.65 crore this fiscal
Opdivo-based treatments are now approved for five indications in upper gastroesophageal cancers
Subscribe To Our Newsletter & Stay Updated
